HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

Status:
Not yet recruiting

Trial end date:
2023-07-15

Target enrollment:

Participant gender:

To evaluate the safety and tolerability of HAIC combined with donafenib and sintilimab in first-line treatment of unresectable ICC.

Phase 2

Zhongda Hospital